Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
2.6
Journals
Current Oncology
Special Issues
An Update on Surgical Treatment for Hepato-Pancreato-Biliary Cancers
share announcement

An Update on Surgical Treatment for Hepato-Pancreato-Biliary Cancers

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 15 May 2024 | Viewed by 3753

Special Issue Editors

Dr. Nikolaos Machairas

E-Mail Website
Guest Editor
2nd Department of Propaedeutic Surgery, National and Kapodistrian University of Athens, Athens, Greece
Interests: HPB surgery; surgical oncology; minimally invasive surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Stylianos Kykalos

E-Mail Website
Guest Editor
2nd Department of Propaedeutic Surgery, National and Kapodistrian University of Athens, Athens, Greece
Interests: surgery; hepatobiliary; pancreas; transplantation; colon cancer; hernia
Dr. Dimitrios Schizas

E-Mail Website
Guest Editor
1st Department of Surgery, National and Kapodistrian University of Athens, Athens, Greece
Interests: esophageal cancer; gastric cancer; pancreatic cancer; immunotherapy; personalized medicine; surgery; medical education
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Significant progress has been noted over the past few decades in the field of surgical management of hepato-pancreatobiliary (HPB) cancers. Through an improved understanding of the functions and anatomy of the liver and pancreas, combined with progress in surgical techniques and accumulation of surgical experience, both short- and long-term outcomes following surgical treatments have improved dramatically. More challenging liver and pancreatic resections with the use of traditional and cutting-edge techniques are now feasible in the context of multidisciplinary team management.

The objective of this Special Issue is to provide an update in the field of surgical treatment of primary and metastatic hepatobiliary as well as pancreatic tumors, and on future challenges to provide a thorough overview of the field as it presently stands. Our issue aims to review outcomes from traditionally used surgical interventions, as well as novel surgical techniques that are emerging in modern clinical practice. We further aim to inspire, inform, and provide both direction and guidance to surgeons and researchers in the field. We strongly encourage authors to submit high-quality research articles focusing on emerging surgical strategies and innovative multidisciplinary treatment protocols for the management of HPB tumors. Original articles as well as review articles, meta-analyses, how-to, and opinion articles are welcome.

You may choose our Joint Special Issue in Cancers.

Dr. Nikolaos Machairas
Dr. Stylianos Kykalos
Dr. Dimitrios Schizas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatocellular carcinoma
  • cholangiocarcinoma
  • klatskin
  • intrahepatic
  • pancreatic
  • ductal adenocarcinoma
  • gallbladder cancer
  • surgery

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 289 KiB  
Article
Incisional Hernia Following Open Pancreaticoduodenectomy: Incidence and Risk Factors at a Tertiary Care Centre
by Carolina González-Abós, Catalina Pineda, Carlos Arrocha, Jordi Farguell, Ignacio Gil and Fabio Ausania
Curr. Oncol. 2023, 30(8), 7089-7098; https://doi.org/10.3390/curroncol30080514 - 25 Jul 2023
Viewed by 1486
Abstract
(1) Background: Incisional hernia (IH) is one of the most common complications following open abdominal surgery. There is scarce evidence on its real incidence following pancreatic surgery. The purpose of this study is to evaluate the incidence and the risk factors associated with [...] Read more.
(1) Background: Incisional hernia (IH) is one of the most common complications following open abdominal surgery. There is scarce evidence on its real incidence following pancreatic surgery. The purpose of this study is to evaluate the incidence and the risk factors associated with IH development in patients undergoing pancreaticoduodenectomy (PD). (2) Methods: We retrospectively reviewed all patients undergoing PD between 2014 and 2020 at our centre. Data were extracted from a prospectively held database, including perioperative and long-term factors. We performed univariate and multivariate analysis to detect those factors potentially associated with IH development. (3) Results: The incidence of IH was 8.8% (19/213 patients). Median age was 67 (33–85) years. BMI was 24.9 (14–41) and 184 patients (86.4%) underwent PD for malignant disease. Median follow-up was 23 (6–111) months. Median time to IH development was 31 (13–89) months. Six (31.5%) patients required surgical repair. Following univariate and multivariate analysis, preoperative hypoalbuminemia (OR 3.4, 95% CI 1.24–9.16, p = 0.01) and BMI ≥ 30 kg/m2 (OR 2.6, 95% CI 1.06–8.14, p = 0.049) were the only factors independently associated with the development of IH. (4) Conclusions: The incidence of IH following PD was 8.8% in a tertiary care center. Preoperative hypoalbuminemia and obesity are independently associated with IH occurrence following PD. Full article
(This article belongs to the Special Issue An Update on Surgical Treatment for Hepato-Pancreato-Biliary Cancers)
12 pages, 2008 KiB  
Article
Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence
by Jianming Yang, Shijie Jiang, Yewu Chen, Jian Zhang and Yinan Deng
Curr. Oncol. 2023, 30(2), 1708-1719; https://doi.org/10.3390/curroncol30020132 - 31 Jan 2023
Cited by 2 | Viewed by 1646
Abstract
Background: The high recurrence rate of hepatocellular carcinoma (HCC) after hepatectomy usually results in poor prognosis. To the best of our knowledge, no study has reported the efficacy of immune checkpoint inhibitors (ICIs) plus targeted therapies on preventing HCC recurrence after hepatectomy. Thus, [...] Read more.
Background: The high recurrence rate of hepatocellular carcinoma (HCC) after hepatectomy usually results in poor prognosis. To the best of our knowledge, no study has reported the efficacy of immune checkpoint inhibitors (ICIs) plus targeted therapies on preventing HCC recurrence after hepatectomy. Thus, the aim of this study was to investigate the benefits and safety of applying adjuvant ICIs plus targeted therapies after hepatectomy for patients at high risk of HCC recurrence. Methods: A total of 196 patients with any risk factors for recurrence who underwent hepatectomy for HCC were reviewed in this retrospective study. Results: Compared with the control group (n = 158), ICIs plus targeted therapies (n = 38) had a significantly higher recurrence-free survival (RFS) rate in univariate analysis (HR, 0.46; 95% confidence interval [CI], 0.24–0.90; p = 0.020), multivariate analysis (adjusted HR, 0.62; 95%CI, 0.49–0.79; p < 0.001) and propensity score-matched analysis (HR, 0.35; 95%CI, 0.16–0.75; p = 0.005). Subgroup analyses also showed that postoperative adjuvant ICIs plus targeted therapies might reduce HCC recurrence in patients with the most of risk factors. Conclusion: Postoperative adjuvant ICI plus targeted therapies may reduces early HCC recurrence in patients with a high risk of recurrence, and the treatments are well tolerated. Full article
(This article belongs to the Special Issue An Update on Surgical Treatment for Hepato-Pancreato-Biliary Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop